

Brandon J Webb

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3257090/brandon-j-webb-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43 papers	743 citations	15 h-index	26 g-index
46 ext. papers	1,111 ext. citations	4.7 avg, IF	4.22 L-index

#	Paper	IF	Citations
43	Simple scoring tool to estimate risk of hospitalization and mortality in ambulatory and emergency department patients with COVID-19.. <i>PLoS ONE</i> , 2022 , 17, e0261508	3.7	0
42	A Novel Program to Provide Drug Recovery Assistance and Outpatient Parenteral Antibiotic Therapy in People Who Inject Drugs.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab629	1	0
41	Association of the Intermountain Risk Score with major adverse health events in patients positive for COVID-19: an observational evaluation of a US cohort.. <i>BMJ Open</i> , 2022 , 12, e053864	3	
40	Evaluation of potential COVID-19 recurrence in patients with late repeat positive SARS-CoV-2 testing. <i>PLoS ONE</i> , 2021 , 16, e0251214	3.7	7
39	Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab331	1	20
38	Developing statewide remdesivir use criteria. <i>American Journal of Health-System Pharmacy</i> , 2021 , 78, 732-735	2.2	1
37	Defining COVID-19-associated hyperinflammatory syndrome in specific populations. <i>Lancet Rheumatology, The</i> , 2021 , 3, e609-e611	14.2	0
36	Epidemiology, Clinical Features, and Outcomes of Coccidioidomycosis, Utah, 2006-2015. <i>Emerging Infectious Diseases</i> , 2021 , 27, 2269-2277	10.2	2
35	Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 1008-1015	4.7	20
34	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. <i>Chest</i> , 2020 , 158, 1896-1911	5.3	20
33	Are Clostridioides difficile infections being overdiagnosed in hematopoietic stem cell transplant recipients?. <i>Transplant Infectious Disease</i> , 2020 , 22, e13279	2.7	2
32	Disseminated toxoplasmosis and haemophagocytic lymphohistiocytosis following chimeric antigen receptor T-cell therapy. <i>British Journal of Haematology</i> , 2020 , 189, e4-e6	4.5	2
31	Strategies for prediction of drug-resistant pathogens and empiric antibiotic selection in community-acquired pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2020 , 26, 249-259	3	0
30	Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	20
29	Deploying an Electronic Clinical Decision Support Tool for Diagnosis and Treatment of Pneumonia Into Rural and Critical Access Hospitals: Utilization, Effect on Processes of Care, and Clinician Satisfaction. <i>Journal of Rural Health</i> , 2020 ,	4.6	1
28	Antimicrobial Stewardship in a Hematological Malignancy Unit: Carbapenem Reduction and Decreased Vancomycin-Resistant Enterococcus Infection. <i>Clinical Infectious Diseases</i> , 2020 , 71, 960-967	11.6	9
27	Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e754-e763	14.2	135

26	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline: A Critical Appraisal by a Global Expert Panel. <i>Chest</i> , 2020 , 158, 1912-1918	5.3	6
25	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial. <i>Annals of the American Thoracic Society</i> , 2020 ,	4.7	15
24	Antibiotic Use and Outcomes After Implementation of the Drug Resistance in Pneumonia Score in ED Patients With Community-Onset Pneumonia. <i>Chest</i> , 2019 , 156, 843-851	5.3	11
23	Decrease in vancomycin-resistant <i>Enterococcus</i> colonization associated with a reduction in carbapenem use as empiric therapy for febrile neutropenia in patients with acute leukemia. <i>Infection Control and Hospital Epidemiology</i> , 2019 , 40, 774-779	2	6
22	Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	34
21	Repurposing an Old Drug for a New Epidemic: Ursodeoxycholic Acid to Prevent Recurrent <i>Clostridioides difficile</i> Infection. <i>Clinical Infectious Diseases</i> , 2019 , 68, 498-500	11.6	12
20	<i>Clostridioides difficile</i> colonization and infection in patients admitted for a first autologous transplantation: Incidence, risk factors, and patient outcomes. <i>Clinical Transplantation</i> , 2019 , 33, e13712	3.8	3
19	Implementation of Real-Time Electronic Clinical Decision Support for Emergency Department Patients with Pneumonia Across a Healthcare System 2019 , 2019, 353-362	0.7	1
18	<i>Clostridioides difficile</i> colonization and infection in patients with newly diagnosed acute leukemia: Incidence, risk factors, and patient outcomes. <i>American Journal of Infection Control</i> , 2019 , 47, 394-399	3.8	5
17	Reply to Babbal et al., "Application of the DRIP Score at a Veterans Affairs Hospital". <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	2
16	Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy187	1	69
15	The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2018 , 20, e12961	2.7	13
14	Vancomycin-Resistant <i>Enterococcus</i> Colonization and Bacteremia and Hematopoietic Stem Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 340-346	4.7	29
13	Prediction of Bloodstream Infection Due to Vancomycin-Resistant <i>Enterococcus</i> in Patients Undergoing Leukemia Induction or Hematopoietic Stem-Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1753-1759	11.6	33
12	Broad- versus Narrow-Spectrum Oral Antibiotic Transition and Outcomes in Health Care-associated Pneumonia. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 200-205	4.7	7
11	Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2652-63	5.9	37
10	Use of Tracheal Aspirate Culture in Newly Intubated Patients with Community-Onset Pneumonia. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 376-81	4.7	12
9	Stewardship in Community Hospitals Optimizing Outcomes and Resources (SCORE): A Cluster-Randomized Controlled Trial Investigating the Impact of Antibiotic Stewardship in 15 Small, Community Hospitals. <i>Open Forum Infectious Diseases</i> , 2016 , 3,	1	4

8	Empiric antibiotic selection and risk prediction of drug-resistant pathogens in community-onset pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2016 , 29, 167-77	5.4	11
7	Room contamination, patient colonization pressure, and the risk of vancomycin-resistant Enterococcus colonization on a unit dedicated to the treatment of hematologic malignancies and hematopoietic stem cell transplantation. <i>American Journal of Infection Control</i> , 2016 , 44, 1110-1115	3.8	16
6	Predicting risk of drug-resistant organisms in pneumonia: moving beyond the HCAP model. <i>Respiratory Medicine</i> , 2015 , 109, 1-10	4.6	40
5	Coxiella burnetii Infection With Severe Hyperferritinemia in an Asplenic Patient. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv125	1	3
4	Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 859-64	5.9	92
3	Guideline-concordant antibiotic therapy and clinical outcomes in healthcare-associated pneumonia. <i>Respiratory Medicine</i> , 2012 , 106, 1606-12	4.6	30
2	Real-World Effectiveness and Tolerability of Monoclonal Antibodies for Ambulatory Patients with Early COVID-19		5
1	Simple Scoring Tool to Estimate Risk of Hospitalization and Mortality in Ambulatory and Emergency Department Patients with COVID-19		3